Abstract:Gene therapy holds great potential for treating almost any disease by gene silencing, protein expression, or gene correction. To efficiently deliver the nucleic acid payload to its target tissue, the genetic material needs to be combined with a delivery platform. Lipid nanoparticles (LNPs) have proven to be excellent delivery vectors for gene therapy and are increasingly entering into routine clinical practice. Over the past two decades, the optimization of LNP formulations for nucleic acid delivery has led to a well-established body of knowledge culminating in the first-ever RNA interference therapeutic using LNP technology, i.e. Onpattro®, and many more in clinical development to deliver various nucleic acid payloads. Screening a lipid library in vivo for optimal gene silencing potency in hepatocytes resulted in the identification of the Onpattro® formulation. Subsequent studies discovered that the key to Onpattro®'s liver tropism is its ability to form a specific "biomolecular corona". In fact, apolipoprotein E (ApoE), among other proteins, adsorbed to the LNP surface enables specific hepatocyte targeting. This proof-of-principle example demonstrates the use of the biomolecular corona for targeting specific receptors and cells, thereby opening up the road to rationally designing LNPs. To date, however, only a few studies have explored in detail the corona of LNPs and how to efficiently modulate the corona remains poorly understood. In this review, we summarize recent discoveries about the biomolecular corona, expanding the knowledge gained with other nanoparticles to LNPs for nucleic acid delivery. In particular, we address how particle stability, biodistribution, and targeting of LNPs can be influenced by the biological environment. Onpattro® is used as a case study to describe both the successful development of an LNP formulation for gene therapy and the key influence of the biological environment. Moreover, we outline the techniques available to isolate and analyze the corona of LNPs, and we highlight their advantages and drawbacks. Finally, we discuss possible implications of the biomolecular corona for LNP delivery and we examine the potential of exploiting the corona as a targeting strategy beyond the liver to develop next-generation gene therapies.

Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.

Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application

Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells

Templated Spherical High Density Lipoprotein Nanoparticles

The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

Lipid Nanoparticles for Nucleic Acid Delivery Beyond the Liver

Tailoring of Biomimetic High-Density Lipoprotein Nanostructures Changes Cholesterol Binding and Efflux

The 60-year evolution of lipid nanoparticles for nucleic acid delivery

Advances in the Formulation and Assembly of Non-Cationic Lipid Nanoparticles for the Medical Application of Gene Therapeutics

Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids

The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy.

Looking Back, Moving Forward: Lipid Nanoparticles as a Promising Frontier in Gene Delivery

Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy

Plasmid DNA Nanoparticles for Nonviral Oral Gene Therapy

Surface modification of lipid nanoparticles for gene therapy

Nucleic Acid-Mediated Intracellular Protein Delivery by Lipid-Like Nanoparticles.

A New Type Gene Delivery System – Gene Nanoparticles

Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy

Modulating the Nature of Ionizable Lipids and Number of Layers in Hyaluronan-Decorated Lipid Nanoparticles for In Vitro Delivery of RNAi

Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery

Hollow Polyethyleneimine Nanoparticles with Drug Loaded DNA for Chemotherapeutic Applications